facebook
twitter
rss
account
search
search
 

Actavis to buy rival Warner Chilcott

May 20, 2013 at 2:06 PM   |   Comments

ZUG, Switzerland, May 20 (UPI) -- Swiss generic drug producer Actavis said it would buy U.S. rival Warner Chilcott for a deal valued at $5 billion.

It is an all-stock deal that provides a premium 5 percent on Warner Chilcott's closing price Friday. Actavis said in a release it agreed to pay 0.16 of a share for each Warner Chilcott share, which comes to $20.08 per share.

Actavis will assume Warner Chilcott's $3.5 billion long-term debt, as well, The New York Times reported.

"We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," Paul Bisaro, Actavis' chief executive, said in a statement.

Anecdotes back that up. Last month, talks to have Actavis sell itself to Valeant Pharmaceuticals collapsed. Meanwhile, the Actavis board turned down offers from others, including Mylan, a source told the Times.

Bisaro said Actavis and Warner Chilcott together "creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential."

"And [it] is supported by a deep pipeline of development programs," he said.

© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Destroyers with ballistic missile defense capability heading to Japan Destroyers with ballistic missile defense capability heading to Japan
2
Warren Buffett loses $2 billion in 2 days on investments Warren Buffett loses $2 billion in 2 days on investments
3
Little girls drop F-bombs for feminism in new FCKH8 video Little girls drop F-bombs for feminism in new FCKH8 video
4
Texas plant converts CO2 to baking soda Texas plant converts CO2 to baking soda
5
Brazil, Argentina to strenghten aerospace cooperation; talk Gripen deal Brazil, Argentina to strenghten aerospace cooperation; talk Gripen deal
Trending News
Around the Web
x
Feedback